


Digital Wellbeing

# My Skin Companion



PRODUCT LAUNCH

PARTNERS: Degetel (France), ELTE (Hungary)



## A smart decision-making tool in dermatology

Every year, more than 100 000 new cases of Melanoma are diagnosed in Europe and more than 22 000 European citizen loose their lives to the disease. These patients need a light and intelligent tool to help them detect melanoma early and increase considerably their chance of surviving

To deal with the dermatologists' insufficiency, it is necessary to provide a smart tool to help people to diagnose skin cancer. Deep learning algorithms, powered by advances in computation and very large datasets, have recently been shown to exceed human performance in visual tasks. It is the moment to use this technology to match the performance of dermatologists at the detection of melanoma. My Skin Companion is a mobile application that is easy to distribute to people who have pigmented moles to know instantly, by

taking pictures, the probability that a mole could be a cancer using Artificial Intelligence technology. The application, developed for iOS and Android smartphones, offers the possibility to map the patient body, to memorize mole's position and to manage the photo history in order to detect changes in the shape and size of the mole: an important information for the diagnosis of melanoma. It is also a tool to package all pictures taken in order to show/send them to dermatologist.



THE FUTURE OF  
EUROPE'S DIGITAL  
INNOVATION

eitdigital.eu  
f o i n t w @EIT\_Digital



EIT Digital is supported by the EIT,  
a body of the European Union

## Competitive Advantages

- Several tools are marketed which help patients to have a medical diagnosis by sending pictures to dermatologists but there is no application with deep neural network
- An artificial intelligence to detect skin tumors is developed in May 2018 by a group of American, German and French researchers : a powerful tool but without medical information system which manages patient records
- No application that maps patient's body in order to memorize skins lesions positions and monitor changes over time

## Target Markets

- End-users: patients and general practitioners
- Customers: health insurances, hospitals and patients
- Markets : European Union especially France, Germany and Belgium

## Status/ Traction

- Partners : Degetel (Activity leader and information system developments) and ELTE (Technology provider)
- Mobile application, medical platform and first version of Artificial Intelligence algorithm produced

## Road Map

### 2019

- startup creation and first version of the product to diagnose dermatoscopic images

### 2020

- final product version providing melanoma probability for smartphone pictures using visual processing and deep neural networks providing

## Leveraged Technologies

MySkinCompanion, as a product issued from Skin Care innovation activity, is a mobile application targeted on patients to follow at any time the evolution of his pigmented lesion. By having on his smartphone, the application is presented in the form of a companion to reassure anxious patients and, in case of emergency, to motivate others to book an appointment with a dermatologist. We will develop also the possibility to manage family members records (children for example).

## Contact



**Hassen HBAIEB**  
Activity Leader

e: [hhbaieb@myskincomapnion.com](mailto:hhbaieb@myskincomapnion.com)  
t: +33 1 41 86 02 00

54 Avenue du Général Leclerc  
9210 | Boulgne Billancourt | France



[myskincompanion.com](http://myskincompanion.com)  
 [@myskincompanion](https://twitter.com/myskincompanion)

**My Skin Companion** is an innovation activity proudly supported by EIT Digital.

EIT Digital supports entrepreneurial teams from research and business organisations in launching new startups and new products in agile 12-month projects called innovation activities. These activities are embedded in EIT Digital's European ecosystem and receive a financial co-investment to package their technology, sign up customers and attract investors.